However, Börgeson et al. have demonstrated that lipoxin A4 and its analogue, Benzo-LXA4, can limit liver expansion, reduce serum alanine aminotransferase levels, and decrease hepatic triglyceride levels in models of obesity-induced liver disease [30]. This evidence concerns the gene GPT and obesity disorder.